Ankrin Therapeutics is a biotech start-up developing first-in-class drugs for cancer treatment in areas of high unmet medical need. Our novel and unique therapeutic strategies are founded on forefront high quality research in cancer biology, epigenetics and DNA repair. We leverage novel, well-characterized protein targets including kinases to develop first-in-class drugs against epigenetic regulators and homologous recombination.